JPRN-UMIN000002792
Recruiting
未知
Multicenter comparative study to examine the efficacy of zoledronic acid in prostate cancer with bone metastasis at different hormone sensitivity status. - Multicenter comparative study to examine the efficacy of zoledronic acid in prostate cancer with bone metastasis at different hormone sensitivity status.
Tama Prostate cancer Bone metastasis Study group0 sites200 target enrollmentNovember 26, 2009
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Tama Prostate cancer Bone metastasis Study group
- Enrollment
- 200
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.History of hypersensitivity for zoledronic acid or other bisphosphonate 2\.Renal dysfunction(serum creatinine more than 3\.0mg/dL) 3\.Active concomititant malignancy 4\.Severe coexisting disease 5\.Invasive dental treatment within 3 months 6\.Other bisphosphonate therapy for injection within 6 months 7\.Not suitable for this trial
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A multicentre study to determine the efficacy and patient acceptability of scalp cooling in the prevention of docetaxel-induced hair lossISRCTN00283877eiden University Medical Centre (LUMC) (The Netherlands)260
Completed
Phase 2
Multi-center study to evaluate the efficacy and to standardize RFA for early breast cancerEarly breast cancerJPRN-UMIN000008675ational Cancer Center Hospital372
Active, not recruiting
Phase 1
A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The Hep-Net International Delta hepatits Interventional Trial II (HIDIT-II) - HIDIT-IITo compare the virological efficacy (HDV-RNA) and safety of 96 weeks of therapy with pegylated interferon-alfa-2a plus tenovofir to 96 weeks of therapy with pegylated interferon-alfa-2a plus placebo for the treatment with chronic delta hepatits virus.MedDRA version: 9.1Level: LLTClassification code 10047455Term: Viral hepatitis B without mention of hepatic coma, with hepatitis deltaEUCTR2008-005560-13-GRMedizinische Hochschule Hannover70
Completed
Not Applicable
A multicenter randomised study comparing the efficacy of adefovir dipivoxil versus pegylated interferon alpha-2a plus placebo versus adefovir dipivoxil plus peglyated interferon alpha-2a for the treatment of chronic delta hepatitisAdults with chronic delta hepatitisInfections and InfestationsISRCTN83587695Hannover Medical School (MHH) (Germany)69
Active, not recruiting
Phase 1
Treatment of delta hepatitis with pegylated interferon-alfa-2a and tenofovir or placeboTo compare the virological efficacy (HDV-RNA) and safety of 96 weeks of therapy with pegylated interferon-alfa-2a plus tenovofir to 96 weeks of therapy with pegylated interferon-alfa-2a plus placebo for the treatment with chronic delta hepatits virus.MedDRA version: 15.1Level: LLTClassification code 10047455Term: Viral hepatitis B without mention of hepatic coma, with hepatitis deltaSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2008-005560-13-DEMedizinische Hochschule Hannover70